An accompanying commentary notes that the move into a new era of type 2 immunity-mediated therapies will bring new opportunities for clinicians and patients, but also new challenges. Biomarkers will increase in importance to help drive precision medicine, but there is a need to understand how to use them, and in particular what cut-off points to apply.
Reslizumab is a humanised monoclonal antibody (IgG4, κ) against the human interleukin-5 (IL-5). It binds specifically to IL-5 and interferes with IL-5 binding to its cell-surface receptor. IL-5 is a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. Reslizumab infusion was recently launched in the UK as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment